The Cost-Effectiveness of Expanding Vaccination with a Cell-Based Influenza Vaccine to Low Risk Adults Aged 50 to 64 Years in the United Kingdom

Background: In response to COVID-19, the UK National Health Service (NHS) extended influenza vaccination in 50- to 64-year-olds from at-risk only to all in this age group for the 2020/21 season. The objective of this research is to determine the cost-effectiveness of continuing to vaccinate all with...

Descripción completa

Detalles Bibliográficos
Autores principales: Kohli, Michele A., Maschio, Michael, Mould-Quevedo, Joaquin F., Ashraf, Mansoor, Drummond, Michael F., Weinstein, Milton C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8228189/
https://www.ncbi.nlm.nih.gov/pubmed/34199912
http://dx.doi.org/10.3390/vaccines9060598

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8228189/
https://www.ncbi.nlm.nih.gov/pubmed/34199912
http://dx.doi.org/10.3390/vaccines9060598

Ejemplares similares